Troriluzole is a third generation prodrug of the glutamate modulating agent, riluzole.

Researchers examined how sex interacts with genetic disease burden to influence clinical symptoms and brain changes in Huntington disease.

Researchers examined whether there is an association between TBI and the subsequent risk for ALS.

After 36 months, patients treated with high dose AMT-130 saw a 75% slowing of disease progression vs the external control.

A phase 1/2 study is currently underway to evaluate SAR446268 in participants aged 10 to 50 years with non-congenital myotonic dystrophy type 1.

Zilganersen is an antisense oligonucleotide designed to block the production of excess GFAP caused by mutations in the GFAP gene.

There are currently no FDA-approved treatments that address the underlying disease progression of MSA.

Researchers conducted a cross-sectional study using the Olink Explore 3072 platform to examine plasma proteomics as a biomarker tool for ALS.

The decision was made based on data from the phase 2b/3 ORION trial.

The original NDA submission included data from the registration-directed phase 3 MOVE-FA trial as well as 2 long-term studies evaluating vatiquinone in FA.

Approved in 2022, Skysona is indicated to slow the progression of neurologic dysfunction in boys 4 to 17 years of age with early, active cerebral adrenoleukodystrophy.

Researchers conducted a nested case-control study drawn from a longitudinal cohort to examine whether combat athletes with substantial exposure to RHI with a history of socioeconomic disadvantage have greater neurodegeneration than those from affluent neighborhoods.

FNP-223 is currently being investigated in a phase 2 trial evaluating the treatment in adults with possible or probable PSP-Richardson syndrome.

Researchers describe development and validation of the HDDMS score, which is a composite score for measuring motor progression of HD in clinical research.

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

Researchers queried the TriNetX research network to examine whether pharmacological suppression of REM sleep can improve sleep disordered breathing and nocturnal hypoxemia in ALS.

About 350 cases are diagnosed in the United States each year, according to the National Institutes of Health (NIH).

Investigators leveraged data from 7 prospective, community-based cohorts across Europe and the United States to examine associations between cardiac function, clinical heart failure, and structural markers on brain magnetic resonance imaging.

Treatment with intravenous (IV) edaravone was associated with fewer reported disease progression milestones and deaths in patients with amyotrophic lateral sclerosis (ALS), according to real-world data published in the Journal of Comparative Effectiveness Research. ALS is a neurodegenerative condition that results in cell neuron death and progressive muscular weakness. The IV formulation of edaravone was…

Researchers conducted a retrospective study to describe and compare resource utilization among decedents with neurodegenerative diseases vs cancer.

Researchers explored the relationship between sodium-glucose cotransporter 2 inhibitor use and risk for dementia and Parkinson disease in patients with diabetes.

In a cross-sectional study, researchers assessed racial and ethnic disparities in time from symptom onset to time of Huntington disease diagnosis.

Findings only for men, but authors say it is premature to counsel against these activities.

Researchers sought to assess the association between mild and complex multimorbidity with structural brain changes in older adults.

In a cross-sectional study, researchers examined death certificate data from 2007 to 2020 to better understand recent trends of CJD in the US.

In a longitudinal cohort study, researchers examined the relationship between blood biomarkers and longitudinal change in cognitive function and regional brain volumes among professional fighters.

In a longitudinal observational study, researchers assessed the treatment effects of metformin on dementia risk among patients with type 2 diabetes.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for valbenazine oral granules.

Researchers sought to assess the safety and efficacy of ravulizumab for adults with amyotrophic lateral sclerosis.